Favorable Stage I and

for determining

[1]  H. Eich,et al.  Long-Term Course of Patients With Stage IA Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A Report From the German Hodgkin Study Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Radford,et al.  Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma. , 2015, The New England journal of medicine.

[3]  R. Greil,et al.  Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin's lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial , 2015, The Lancet.

[4]  Zuofeng Li,et al.  Involved-node proton therapy in combined modality therapy for Hodgkin lymphoma: results of a phase 2 study. , 2014, International journal of radiation oncology, biology, physics.

[5]  H. Eich,et al.  Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). , 2014, International journal of radiation oncology, biology, physics.

[6]  F. Merli,et al.  Clinical Investigation : Lymphoma Involved-Site Image-Guided Intensity Modulated Versus 3 D Conformal Radiation Therapy in Early Stage Supradiaphragmatic Hodgkin Lymphoma , 2022 .

[7]  J. Raemaekers,et al.  Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Y. Natkunam,et al.  Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  R. Warnke,et al.  Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  M. Aznar,et al.  Clinical Investigation : Lymphoma Involved Node Radiation Therapy : An Effective Alternative in Early-Stage Hodgkin Lymphoma , 2013 .

[11]  R. Advani,et al.  Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  S. Tofani,et al.  Different IMRT solutions vs. 3D-Conformal Radiotherapy in early stage Hodgkin’s lymphoma: dosimetric comparison and clinical considerations , 2012, Radiation oncology.

[13]  Zuofeng Li,et al.  Effective dose reduction to cardiac structures using protons compared with 3DCRT and IMRT in mediastinal Hodgkin lymphoma. , 2012, International journal of radiation oncology, biology, physics.

[14]  Bingshu E. Chen,et al.  ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma. , 2012, The New England journal of medicine.

[15]  P. Borchmann,et al.  Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group. , 2011, Blood.

[16]  R. Advani,et al.  Abbreviated 8-week chemotherapy (CT) plus involved node radiotherapy (INRT) for nonbulky stage I-II Hodgkin lymphoma: Preliminary results of the Stanford G5 Study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  T. Messai,et al.  Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. , 2011, International journal of radiation oncology, biology, physics.

[18]  R. Greil,et al.  Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. , 2010, The New England journal of medicine.

[19]  L. Specht,et al.  Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin’s lymphoma: a systematic review , 2010, Haematologica.

[20]  M. Hauptmann,et al.  Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. , 2009, International journal of radiation oncology, biology, physics.

[21]  L. Robison,et al.  Radiation dose and breast cancer risk in the childhood cancer survivor study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  R. Gascoyne,et al.  Involved-nodal radiation therapy as a component of combination therapy for limited-stage Hodgkin's lymphoma: a question of field size. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. D. De Bruin,et al.  Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. , 2008, Journal of the National Cancer Institute.

[24]  H. Eich,et al.  Involved-Node Radiotherapy in Early-Stage Hodgkin’s Lymphoma , 2008, Strahlentherapie und Onkologie.

[25]  R. Müller,et al.  Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Raemaekers,et al.  Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. , 2007, The New England journal of medicine.

[27]  F. d'Amore,et al.  Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  H. Eich,et al.  Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  R. Tsang,et al.  Fertility among female hodgkin lymphoma survivors attempting pregnancy following ABVD chemotherapy , 2007, Hematological oncology.

[30]  A. Horwich,et al.  Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. , 2007, Journal of the National Cancer Institute.

[31]  M. Salvatore,et al.  Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans , 2007, Leukemia & lymphoma.

[32]  V. Diehl,et al.  Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[33]  S. Pileri,et al.  Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[34]  J. Raemaekers,et al.  Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  E. Noordijk,et al.  Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[36]  N. Mikhaeel,et al.  Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[37]  E. Noordijk,et al.  First results of the EORTC-GELA H9 randomized trials: the H9-F trial (comparing 3 radiation dose levels) and H9-U trial (comparing 3 chemotherapy schemes) in patients with favorable or unfavorable early stage Hodgkin’s lymphoma (HL) , 2005 .

[38]  A. Zelenetz,et al.  Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. , 2004, Blood.

[39]  G. Bonadonna,et al.  ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  C. Pepine,et al.  Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of hodgkin lymphoma treated with radiation therapy. , 2003, JAMA.

[41]  Dirk Hasenclever,et al.  Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  M. Stovall,et al.  Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. , 2003, JAMA.

[43]  A. Broeks,et al.  Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. , 2003, Journal of the National Cancer Institute.

[44]  P. Davis,et al.  Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  M. Stovall,et al.  Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  J. Friedberg,et al.  Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  John D Boice,et al.  Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. , 2002, Journal of the National Cancer Institute.

[48]  S. Horning,et al.  Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  R. Fisher,et al.  Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[50]  A. Hagenbeek,et al.  Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  T. Lister,et al.  Risk of second malignancy after Hodgkin's disease in a collaborative British cohort: the relation to age at treatment. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  V. Diehl,et al.  Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  L. Kalish,et al.  Long-term survival in Hodgkin's disease relative impact of mortality, second tumors, infection, and cardiovascular disease. , 1995, The cancer journal from Scientific American.

[54]  A. Hagenbeek,et al.  Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  S. Kvaløy,et al.  Second malignancies after treatment of Hodgkin's disease: the influence of treatment, follow-up time, and age. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  K. Propert,et al.  Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. , 1992, The New England journal of medicine.

[57]  C. Coleman,et al.  Stage IA and IIA supradiaphragmatic Hodgkin's disease: prognostic factors in surgically staged patients treated with mantle and paraaortic irradiation. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[58]  R. Weichselbaum,et al.  Extended mantle radiation therapy for pathologic stage I and II Hodgkin's disease. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[59]  S. Rosenberg,et al.  The management of stage I--II Hodgkin's disease with irradiation alone or combined modality therapy: the Stanford experience. , 1982, Blood.

[60]  Matthew P. Goetz,et al.  NCCN CLINICAL PRACTICE GUIDELINES IN ONCOLOGY , 2019 .

[61]  Ronald C. Chen,et al.  Early-stage, lymphocyte-predominant Hodgkin's lymphoma: patient outcomes from a large, single-institution series with long follow-up. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  Martin Hutchings,et al.  FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.

[63]  K. Naresh,et al.  Consolidation radiation after complete remission in Hodgkin's disease following six cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine chemotherapy: is there a need? , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[64]  M Tubiana,et al.  The EORTC trials for limited stage Hodgkin's disease. The EORTC Lymphoma Cooperative Group. , 1992, European journal of cancer.

[65]  M Tubiana,et al.  Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin's disease. The EORTC Lymphoma Group controlled clinical trials: 1964-1987. , 1989, Blood.